Estimates of worldwide burden of cancer in 2008: GLOBOCAN, Int J Cancer, vol.127, pp.2893-917, 2008. ,
SEER data submission, Cancer Statistics Review, 1975. ,
Age-specific cancer incidence rates increase through the oldest age groups, Am J Med Sci, vol.348, pp.65-70, 2014. ,
Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology, Ann Oncol, vol.25, pp.1270-83, 2014. ,
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-smallcell lung cancer: IFCT-0501 randomised, Lancet, vol.378, pp.1079-88, 2011. ,
, Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group, J Natl Cancer Inst, vol.91, pp.66-72, 1999.
Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904), J Clin Oncol, vol.24, pp.3657-63, 2006. ,
First line chemotherapy with gemcitabine in advanced nonsmall cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule, Lung Cancer, vol.47, pp.405-417, 2005. ,
Erlotinib in previously treated non-small-cell lung cancer, N Engl J Med, vol.353, pp.123-155, 2005. ,
Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21, J Clin Oncol, vol.26, pp.2350-2357, 2008. ,
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung, J Clin Oncol, vol.30, pp.1122-1130, 2012. ,
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, vol.362, pp.2380-2388, 2010. ,
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, Lancet Oncol, vol.12, pp.735-777, 2011. ,
Screening for epidermal growth factor receptor mutations in lung cancer, N Engl J Med, vol.361, pp.958-67, 2009. ,
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations, J Clin Oncol, vol.31, pp.3327-3361, 2013. ,
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial, Lancet Oncol, vol.15, pp.213-235, 2014. ,
Firstline gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy, J Clin Oncol, vol.27, pp.1394-400, 2009. ,
First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study, J Thorac Oncol, vol.7, pp.1417-1439, 2012. ,
Clinical outcomes in elderly patients administered gefitinib as firstline treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group study, Med Oncol, vol.30, p.450, 2013. ,
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, vol.45, pp.228-275, 2009. ,
An evaluation of elderly patients (>/ = 70 years old) enrolled in Phase I clinical trials at University of Texas Health Science Center at San Antonio-Cancer Therapy Research Center from, Journal of geriatric oncology, vol.5, pp.65-70, 2009. ,
Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?, Clin Exp Med, 2017. ,
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, openlabel, randomised phase 3 trial, Lancet Oncol, vol.13, pp.239-285, 2012. ,
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial, Lancet Oncol, vol.17, pp.577-89, 2016. ,
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L, J Clin Oncol, vol.34, pp.3248-57, 2016. ,
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study, JAMA oncology, vol.2, pp.305-317, 2016. ,
Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study, Target Oncol, vol.11, pp.167-74, 2016. ,
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study, J Clin Oncol, vol.34, pp.1476-83, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01282337
Drug-induced effects on erlotinib metabolism, N Engl J Med, vol.365, pp.379-80, 2011. ,